ABBVIE INC (1ABBV.MI) Stock Fundamental Analysis
Europe - BIT:1ABBV - US00287Y1091 - Common Stock
194.8 EUR
-6.2 (-3.08%)
1ABBV gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. While 1ABBV is still in line with the averages on profitability rating, there are concerns on its financial health. 1ABBV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1ABBV was profitable.
In the past year 1ABBV had a positive cash flow from operations.
In the past 5 years 1ABBV has always been profitable.
In the past 5 years 1ABBV always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 2.71%, 1ABBV is doing good in the industry, outperforming 76.62% of the companies in the same industry.
1ABBV has a better Return On Invested Capital (13.81%) than 90.91% of its industry peers.
1ABBV had an Average Return On Invested Capital over the past 3 years of 13.67%. This is in line with the industry average of 12.96%.
The last Return On Invested Capital (13.81%) for 1ABBV is above the 3 year average (13.67%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROIC | 13.81% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
1.3 Margins
1ABBV has a better Profit Margin (6.38%) than 80.52% of its industry peers.
1ABBV's Profit Margin has declined in the last couple of years.
1ABBV has a better Operating Margin (31.27%) than 90.91% of its industry peers.
In the last couple of years the Operating Margin of 1ABBV has declined.
With a decent Gross Margin value of 70.93%, 1ABBV is doing good in the industry, outperforming 64.94% of the companies in the same industry.
In the last couple of years the Gross Margin of 1ABBV has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% |
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1ABBV is creating some value.
1ABBV has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1ABBV has more shares outstanding
Compared to 1 year ago, 1ABBV has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.40 indicates that 1ABBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
1ABBV's Altman-Z score of 2.40 is fine compared to the rest of the industry. 1ABBV outperforms 63.64% of its industry peers.
The Debt to FCF ratio of 1ABBV is 3.86, which is a good value as it means it would take 1ABBV, 3.86 years of fcf income to pay off all of its debts.
1ABBV's Debt to FCF ratio of 3.86 is fine compared to the rest of the industry. 1ABBV outperforms 79.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Altman-Z | 2.4 |
ROIC/WACC1.52
WACC9.09%
2.3 Liquidity
A Current Ratio of 0.74 indicates that 1ABBV may have some problems paying its short term obligations.
The Current ratio of 1ABBV (0.74) is worse than 76.62% of its industry peers.
1ABBV has a Quick Ratio of 0.74. This is a bad value and indicates that 1ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of 1ABBV (0.61) is worse than 77.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
1ABBV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
Measured over the past 5 years, 1ABBV shows a small growth in Earnings Per Share. The EPS has been growing by 2.51% on average per year.
Looking at the last year, 1ABBV shows a small growth in Revenue. The Revenue has grown by 6.05% in the last year.
Measured over the past years, 1ABBV shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
3.2 Future
1ABBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.59% yearly.
The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 21.36, which indicates a rather expensive current valuation of 1ABBV.
Based on the Price/Earnings ratio, 1ABBV is valued cheaper than 80.52% of the companies in the same industry.
1ABBV is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.89, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 15.55, 1ABBV is valued correctly.
Based on the Price/Forward Earnings ratio, 1ABBV is valued cheaper than 87.01% of the companies in the same industry.
1ABBV is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.59, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.36 | ||
| Fwd PE | 15.55 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1ABBV is valued a bit cheaper than 77.92% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1ABBV is valued cheaper than 84.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.91 | ||
| EV/EBITDA | 17.28 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1ABBV does not grow enough to justify the current Price/Earnings ratio.
1ABBV has a very decent profitability rating, which may justify a higher PE ratio.
1ABBV's earnings are expected to grow with 16.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.45
PEG (5Y)8.51
EPS Next 2Y19.88%
EPS Next 3Y16.85%
5. Dividend
5.1 Amount
1ABBV has a Yearly Dividend Yield of 2.87%.
Compared to an average industry Dividend Yield of 9.04, 1ABBV pays a better dividend. On top of this 1ABBV pays more dividend than 94.81% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, 1ABBV has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
5.2 History
On average, the dividend of 1ABBV grows each year by 7.72%, which is quite nice.
Dividend Growth(5Y)7.72%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
1ABBV pays out 304.54% of its income as dividend. This is not a sustainable payout ratio.
The dividend of 1ABBV is growing, but earnings are growing more, so the dividend growth is sustainable.
DP304.54%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
BIT:1ABBV (10/15/2025, 7:00:00 PM)
194.8
-6.2 (-3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners74.42%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap344.13B
Revenue(TTM)58.33B
Net Income(TTM)3.72B
Analysts79.46
Price Target197.82 (1.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.87% |
Yearly Dividend5.38
Dividend Growth(5Y)7.72%
DP304.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.04%
Min EPS beat(2)0.95%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.75%
Min EPS beat(4)0.02%
Max EPS beat(4)1.14%
EPS beat(8)7
Avg EPS beat(8)0.76%
EPS beat(12)9
Avg EPS beat(12)0.46%
EPS beat(16)11
Avg EPS beat(16)0.4%
Revenue beat(2)2
Avg Revenue beat(2)0.93%
Min Revenue beat(2)0.63%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.24%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)5
Avg Revenue beat(12)-0.32%
Revenue beat(16)5
Avg Revenue beat(16)-0.81%
PT rev (1m)4.92%
PT rev (3m)5.18%
EPS NQ rev (1m)-45.1%
EPS NQ rev (3m)-44.14%
EPS NY rev (1m)-12.38%
EPS NY rev (3m)-13.98%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)1.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.36 | ||
| Fwd PE | 15.55 | ||
| P/S | 6.85 | ||
| P/FCF | 21.91 | ||
| P/OCF | 20.72 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 17.28 |
EPS(TTM)9.12
EY4.68%
EPS(NY)12.52
Fwd EY6.43%
FCF(TTM)8.89
FCFY4.56%
OCF(TTM)9.4
OCFY4.83%
SpS28.43
BVpS-0.09
TBVpS-45.26
PEG (NY)3.45
PEG (5Y)8.51
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.71% | ||
| ROE | N/A | ||
| ROCE | 18.72% | ||
| ROIC | 13.81% | ||
| ROICexc | 14.74% | ||
| ROICexgc | 370.81% | ||
| OM | 31.27% | ||
| PM (TTM) | 6.38% | ||
| GM | 70.93% | ||
| FCFM | 31.27% |
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.86 | ||
| Debt/EBITDA | 2.58 | ||
| Cap/Depr | 12.62% | ||
| Cap/Sales | 1.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 72.74% | ||
| Profit Quality | 489.9% | ||
| Current Ratio | 0.74 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z | 2.4 |
F-Score6
WACC9.09%
ROIC/WACC1.52
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%12.08%
EPS Next Y6.19%
EPS Next 2Y19.88%
EPS Next 3Y16.85%
EPS Next 5Y13.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%6.65%
Revenue Next Year8.23%
Revenue Next 2Y8.64%
Revenue Next 3Y8.27%
Revenue Next 5Y7.22%
EBIT growth 1Y13.81%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year20.95%
EBIT Next 3Y15.22%
EBIT Next 5Y11.27%
FCF growth 1Y-26.45%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-24.5%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%
ABBVIE INC / 1ABBV.MI FAQ
Can you provide the ChartMill fundamental rating for ABBVIE INC?
ChartMill assigns a fundamental rating of 5 / 10 to 1ABBV.MI.
Can you provide the valuation status for ABBVIE INC?
ChartMill assigns a valuation rating of 6 / 10 to ABBVIE INC (1ABBV.MI). This can be considered as Fairly Valued.
What is the profitability of 1ABBV stock?
ABBVIE INC (1ABBV.MI) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for 1ABBV stock?
The Price/Earnings (PE) ratio for ABBVIE INC (1ABBV.MI) is 21.36 and the Price/Book (PB) ratio is -2183.6.
Can you provide the financial health for 1ABBV stock?
The financial health rating of ABBVIE INC (1ABBV.MI) is 3 / 10.